BofA raises Sino Biopharmaceutical target to HK$7.3 amid China drug innovation
AI Summary- BofA Securities raised Sino Biopharmaceutical’s target price and reiterated its Buy rating.
- HK$7.3 became Sino Biopharmaceutical’s new target price, up from HK$7.1.
- BofA met nine healthcare companies and one oncology expert during its Shanghai sector tour.